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Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-
valvular atrial fibrillation 
 
Abstract 
 
Introduction Oral anticoagulation is central to the management of patients with atrial fibrillation 
(AF) and at least one additional stroke risk factor. For decades, the vitamin K antagonists (e.g. 
warfarin) remained the only oral anticoagulant available for stroke prevention in AF. The non-
vitamin K oral anticoagulants (NOACs) are now available, and these drugs include the direct 
thrombin inhibitors and factor Xa inhibitors. The latter class includes edoxaban that has recently 
been approved for stroke prevention in AF by United States Food and Drug Administration and 
European Medicine Agency. In line with other NOACs, edoxaban avoids the many limitations of 
warfarin associated with variability of anticoagulation effect and multiple food and drug 
interactions. 
Areas covered In this review, the currently available evidence on edoxaban in patients with non-
valvular AF is discussed. The pharmacology, efficacy and safety, and current aspects of use of 
edoxaban in patients with non-valvular AF for stroke and thromboembolism prevention are 
reviewed. 
Expert opinion Phase III trial on edoxaban for stroke prevention in non-valvular AF confirms 
non-inferiority of edoxaban compared to well-managed warfarin both in terms of efficacy and 
safety. Currently ongoing and future trials as well as real-world data are warranted to confirm its 
effectiveness and safety for chronic anticoagulation and improve evidence in other areas which 
are lacking evidence where NOAC use remains controversial. 
 
Key words: edoxaban, warfarin, oral anticoagulation, atrial fibrillation, efficacy, safety. 
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1. Introduction 
Cardiovascular diseases are frequently associated with thrombotic complications, e.g., stroke, 
pulmonary embolism, acute coronary syndrome, which together result in high disability and 
mortality rate. There were 5.9 million stroke deaths recorded in the 2010 worldwide, half of 
which were due to ischaemic stroke caused by thrombosis. This represents a 25% increase during 
the two decades and the trend is likely to be continued [1].  
 
Atrial fibrillation (AF) is the most common sustained arrhythmia affecting 1-3% of general 
population steadily rising in an age-dependent manner. AF is one of major contributors to stroke 
morbidity and mortality by increasing the risk of stroke five-fold [2, 3]. Moreover AF is often 
asymptomatic, and often diagnosed opportunistically or only after presentation with a 
complication, such as stroke or heart failure; hence, the real prevalence of AF is likely to be even 
higher [4]. The absence of clinical symptoms of arrhythmia does not necessarily mean lower 
stroke risk, resulting in asymptomatic patients being at particular risk because of absence of 
timely initiated antithrombotic therapy. As a result AF is often diagnosed after stroke has already 
developed, or remains undiagnosed if paroxysms of arrhythmia are short and infrequent [5]. 
 
Stroke and systemic embolism (SE) prevention with oral anticoagulation (OAC) is the mainstay 
of AF management. Lone AF carries a low risk of stroke and represents the minority of patients 
for whom OAC is not indicated because of low stroke risk, and the benefits of stroke prevention 
with OAC are not outweighed by increased risk of bleeding [6]. The vast majority of AF patients 
have one or more additional stroke risk factors, including heart failure, arterial hypertension, 
diabetes mellitus, previous history of stroke or transient ischaemic attack, atherosclerotic arterial 
disease, age and female gender, which were jointly combined in the CHA2DS2-VASc score 
(Table 1) [7-9]. With 1 stroke risk factor, the stroke risk increases from 0.04-2.4 %/year to 0.55-
6.6 %/year and this should trigger initiation of OAC [10]. Female gender is considered as stroke Ре
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risk factor only in conjunction with another risk factor, i.e. the CHA2DS2-VASc score = 2 is the 
threshold for OAC in females [11].  
 
To minimize probability of bleeding with OAC, especially major bleeds, risk of bleeding has to 
be assessed as well, e.g. with the HAS-BLED score (Table 1) [7, 8, 12]. Stroke and bleeding risk 
factors overlap, but higher bleeding risk results into higher net clinical benefit of OAC [13]. 
Hence, a high HAS-BLED score (≥3) should not be used to rule out eligible patients for OAC 
based on stroke risk assessment but to control modifiable risk factors appropriately. 
 
Anticoagulant therapy is available as vitamin K antagonists (VKAs), e.g. warfarin, and non-
VKA oral anticoagulants (NOACs) [14]. Despite being the ‘all-purpose’ oral anticoagulant with 
the longest experience in various clinical settings, warfarin remains an ‘inconvenient’ drug both 
for patients and physicians due to its slow onset and offset of action, variability of 
anticoagulation effect, as determined by genetic polymorphism of enzymes, multiple food and 
drug interactions, etc. – leading the requirement to stay in a narrow therapeutic window of 
international normalized ratio (INR) of 2.0-3.0 that needs to be monitored regularly.  
 
On the contrary NOACs allow us to overcome major drawbacks of warfarin, i.e. they offer fast, 
predictable and stable anticoagulation effect with a fixed dose without need for laboratory 
monitoring and minor food and drug interactions [15, 16]. Currently approved NOACs include 
direct thrombin inhibitor dabigatran and factor Xa inhibitors apixaban, rivaroxaban, and 
edoxaban. 
 
The current review is focused on the pharmacology, efficacy and safety of factor Xa inhibitor 
edoxaban that is the latest NOAC approved by the European Medicines Agency (EMA) and Ре
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United States Food and Drug Administration (FDA) as well as in Japan and Switzerland for 
stroke and SE prevention in non-valvular AF.  
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2. Pharmacology of edoxaban 
 
The coagulation cascade includes extrinsic pathway that is activated by exposure of blood to 
tissue factor. It results in synthesis of a small amount of thrombin, but the latter allows 
amplification of intrinsic pathway via activation of a variety of factors in the coagulation cascade 
(e.g., factors V, VIII, XI, XIII) and synthesis of greater amount of thrombin [17].  
 
Edoxaban rapidly and selectively inhibits enzymatic activity of factor Xa, key enzyme located at 
the confluence of the intrinsic and extrinsic coagulation pathways (common pathway). It binds to 
free factor Xa, factor Xa within prothrombinase complex as well as clot-associated factor Xa that 
eventually leads to downstream dose-dependent blockade of prothrombin to thrombin conversion 
[18]. One inhibited molecule of factor Xa prevents conversion of approximately 1000 molecules 
of prothrombin to thrombin [15]. 
 
Direct factor Xa inhibition also offers pleiotropic effects not related to anticoagulation per se. 
Factor Xa contributes to atherosclerosis via the activation of proteinase-activated receptors PAR-
1 and PAR-2 signalling as well as tissue factor expression in vascular endothelial cells and 
smooth muscle cells, synthesis of inflammatory cytokines such as interleukin-6, tumor necrosis 
factor-α, and monocyte chemoattractant protein-1, abnormal cell proliferation and extracellular 
matrix accumulation [18, 19]. Thus, factor Xa inhibition in experimental works resulted in 
abrogation of aforementioned mechanisms towards slowing of atherosclerosis progression and 
stabilization of advanced atherosclerotic plaques. Edoxaban and other NOACs do not cause 
vascular calcification because of no effect on matrix Gla-protein (MGP) as VKAs do [19]. 
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Edoxaban is supplied as edoxaban tosylate monohydrate. In studies on pharmacokinetics and 
pharmacodynamics of edoxaban it was found to be rapidly absorbed predominantly in the 
proximal small intestine with an oral bioavailability of 61.8%, 95% confidence interval (CI) 
57.7-66.2% in healthy adults [20, 21]. 
 
Peak plasma concentration (Cmax) and peak anti-factor (F)Xa activity of 2.68 IU/mL was 
achieved in approximately 1.5 hours, furthermore prothrombin fragment 1+2, thrombin-
antithrombin complex, and platelet activation marker β-thromboglobulin are all were reduced, 
indicating inhibition of thrombin generation and platelet activation. There was also close 
correlation with prothrombin time (PT), followed by INR and activated partial thromboplastin 
time (aPTT). Sustained inhibition of coagulation after oral administration above baseline level is 
observed for up to 24 hours [22-25]. The terminal half-life of edoxaban 60 mg is 10 to 14 hours 
[26].  
 
Unchanged edoxaban is the predominant form in plasma, and over 70% is excreted unchanged. 
There is minimal metabolism via hydrolysis mediated by carboxylesterase-1 with formation of 
major metabolite M4, and also conjugation, and oxidation by CYP3A4. 62.2% of edoxaban are 
eliminated in faeces and 35.4% - in urine [27]. Notwithstanding the role of the kidneys in the 
elimination of edoxaban and its relatively low protein binding in patients with end stage renal 
disease, edoxaban exposure is not affected by haemodialysis [28]. 
 
Patients gender and ethnicity as well as food intake were shown to have no effect on 
pharmacology of edoxaban [29, 30] while low body weight, i.e. 60 kg or lower, was associated 
with higher trough edoxaban concentration (Cmin) and, eventually, higher rate of bleeding 
complications [31, 32]. 
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Edoxaban is a substrate of P-gp (permeability glycoprotein) efflux transporter in the intestine but 
not of other major uptake transporters, e.g. OAT1, OAT3, OCT1, OCT2, OATP1B1, and 
OATP1B3, resulting in drug-drug interactions of P-gp inducers and inhibitors [27, 33]. When co-
administered with a P-gp inhibitor quinidine, area under time-concentration curve (AUC) and 
Cmax of edoxaban increased by 76.7% and 85.4%; dronedarone - 84.5 and 45.8 %, verapamil - 
52.7 and 53.3, amiodarone - 39.8% and 66.0%, respectively [34]. Combination of digoxin with 
edoxaban results in minor increase of AUC and Cmax of the latter - by 9.5 and 15.6%, 
respectively, while atorvastatin caused increase of AUC of edoxaban by 1.7% and a decrease of 
Cmax by 14.2% [34].  
 
P-gp inducer rifampin was found to reduce oral bioavailability of edoxaban and to increase its 
excretion through induction of P-gp. Metabolism of edoxaban with synthesis of its metabolite 
M6 (through CYP3A4/5) and M4 (due to the inhibition of OATP1B1 and induction of 
carboxylesterase-1) was increased. Overall concomitant administration of rifampin with 
edoxaban resulted in an approximate 34 % decrease in total exposure to edoxaban but three-fold 
increase in exposure to its metabolites [35]. 
 
Pharmacological characteristics of edoxaban are summarized in the Table 2. Edoxaban with 
respect to its pharmacological characteristics is broadly similar to other factor Xa inhibitors and 
direct thrombin inhibitor dabigatran etexilate (e.g., time to maximum plasma concentration, half-
life time, interactions with drugs which affect P-gp transporter). One of the most important 
characteristics that makes NOACs different and should be considered in clinical practice is a 
renal clearance, that is the highest for dabigatran (80%); edoxaban is half-cleared by kidneys 
(50%) while renal clearance of apixaban and rivaroxaban is 27% and 35%, respectively [6, 15].  
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3. Edoxaban trials 
 
In a safety, tolerability, pharmacokinetic, and pharmacodynamic phase I study of edoxaban 
healthy adults were administered range of doses – either single dose (n=85) of 10 to 150 mg once 
daily (qd) or multiple doses (n=36) of 90 and 120 mg qd, 60 mg twice daily (bid). Both single 
and multiple doses were well tolerated. There were no dose-dependent increase in treatment-
emergent adverse events, of which majority were mild, and no serious adverse events were 
observed [22]. 
 
Two phase II dose-ranging studies were performed, randomized AF patients who required OAC 
for stroke prevention, to double-blind edoxaban and open-label dose-adjusted warfarin (INR 2.0–
3.0) arms. In the study by Weitz et al. four dosing regimes of edoxaban were tested: 30 mg qd, 
30 mg bid, 60 mg qd, 60 mg bid, in predominantly Caucasian population (n=1146) while 
Yamashita et al. tested three regimes: 30 mg qd, 45 mg qd, and 60 mg qd, in 536 Asian AF 
patients [31, 36]. Patients were followed-up for twelve weeks. The major and consistent finding 
from both studies was that qd regime of edoxaban administration was safer in terms of major and 
clinically relevant non-major bleeding, and no differences were observed between edoxaban and 
warfarin arms [31, 36]. On the contrary, twice a day regimes of edoxaban were both associated 
with significantly higher bleeding rate compared to warfarin. For example in the study of Weitz 
et al. major and clinically relevant non-major bleeding occurred in 3.2% of patients randomized 
to warfarin, 3.8% and 3.0% in edoxaban 60 mg qd and 30 mg qd, respectively, versus 10.6% and 
7.8% in edoxaban 60 mg bid and 30 mg bid, respectively [36].  
 
These data was further confirmed in the pooled population pharmacokinetic analysis of phase I 
and phase II studies to support dose selection for a phase III study. Moderate renal impairment 
and concomitant strong P-gp inhibitors were found to be the main factors influencing on the Ре
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pharmacokinetics of edoxaban with the necessity to reduce the dose by 50%. Steady-state 
concentration of edoxaban showed the strongest association with the bleeding events [37]. Given 
that Cmin is higher with bid regime, edoxaban 30 mg qd (low dose) and 60 mg qd (high dose) as 
well as reduced based on patients characteristics to 15 mg qd and 30 mg qd dosing regimes were 
chosen for the phase III trial [37]. 
 
The ENGAGE AF – TIMI 48 (Effective anticoagulation with factor xa next generation in atrial 
fibrillation – thrombolysis in myocardial infarction 48) trial was the largest multinational phase 
III study with randomized, non-inferiority, double-blind, double-dummy design, compared 
efficacy and safety of two doses of edoxaban against dose-adjusted warfarin in patients with 
non-valvular AF (Table 3) [38, 39]. Thus, the ENGAGE AF – TIMI 48 had the same design as 
other phase III trials with factor Xa inhibitors (e.g., rivaroxaban and apixaban) while the RE-LY 
trial with dabigatran was open label between dabigatran and warfarin arms, but double blind 
between 2 arms with different doses of dabigatran. Patient cohorts among the NOACs trials had 
some differences that might affect interpretation of trial results [40]. For example, patients 
involved in the ENGAGE AF – TIMI 48 trial had mean CHADS2 of 2.8 that was higher than in 
the trials with dabigatran and apixaban (2.1), but lower than in trial with rivaroxaban (3.5). The 
latter corresponds to history of stroke among study participants [6, 15]. Patients in the ENGAGE 
AF – TIMI 48 trial had the highest time in therapeutic range in warfarin arms and 
discontinuation rate compared to other NOACs trials [6, 15]. 
 
The dose was halved if any of the following characteristics were present at the time of 
randomization or during the study: creatinine clearance (CrCl) of 30 to 50 ml/min, a body weight 
of ≤60 kg, or the concomitant use of potent P-gp inhibitors (verapamil, quinidine, or dronedaron) 
[39]. Patients with CHADS2 score ≥2 were included. The median duration of follow-up was 2.8 Ре
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years. In the warfarin arm there was good quality anticoagulation control with median time in 
therapeutic range (TTR) of 68.4% (interquartile range 56.5 to 77.4) [39]. 
 
In terms of efficacy both edoxaban regimes were found to be non-inferior to warfarin in the 
intention-to-treat analysis [39]. There was a trend toward better efficacy of high dose edoxaban 
versus warfarin for stroke and SE prevention (hazard ratio [HR] 0.87, 97.5% CI 0.73–1.04) that 
was lacking for low-dose edoxaban. In an on-treatment analysis, high dose edoxaban was more 
effective than warfarin (HR 0.79; 97.5% CI 0.63 to 0.99) [39]. When both ischaemic and 
haemorrhagic strokes were analyzed in an on-treatment analysis high dose edoxaban was also 
superior to well managed warfarin (HR 0.80, 95% CI 0.65–0.98) [41]. 
 
Importantly, both dosing regimes of edoxaban were associated with reduced cardiovascular 
mortality: HR 0.86, 95% CI 0.77–0.97, and HR 0.85, 95% CI 0.76–0.96, for edoxaban 60 mg qd 
and 30 mg qd, respectively. There was also a borderline reduction of all-cause mortality with 
high dose edoxaban (HR 0.92, 95% CI 0.83–1.01) that reached significance with low dose 
edoxaban (HR 0.87, 95% CI 0.79–0.96) [39]. 
 
In terms of safety outcomes, both edoxaban dosing regimes were associated with significantly 
lower risk of bleeding events compared to warfarin, including major, major plus clinically 
relevant non-major bleeding, intracranial haemorrhage (ICH), and any bleeding [39]. 
Gastrointestinal bleeding was less frequent with edoxaban 30 mg qd, but more frequent with 
edoxaban 60 mg qd [39]. 
 
Noteworthy, development of a transition protocol from blinded edoxaban to open warfarin or 
from blinded warfarin to open warfarin at the end of the ENGAGE AF – TIMI 48 trial allowed Ре
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to avoid excessive rates of stroke or major bleeding as it was seen in the ROCKET AF trial with 
rivaroxaban and the ARISTOTLE with apixaban [42, 43]. 
 
Edoxaban was shown to perform equally in majority of subgroups specified according to age, 
gender, body weight, stroke risk, etc. (Table 4). However there was a significant interaction 
between efficacy of edoxaban and kidney function. In patients with mild kidney dysfunction 
(CrCL of 50 to 80 ml/ min) edoxaban 60 mg qd was found to reduce the risk of stroke and SE 
(HR 0.51, 95% CI 0.38-0.69) while in patients with normal CrCl of 80 ml/min or more the risk 
of stroke and SE was higher than in patients on warfarin (HR 1.41, 95% CI 0.97-2.05) [44]. 
Results were also worse for other end points such as ischaemic stroke (HR 0.62, 95% CI 0.43-
0.87 versus HR 1.58, 95 % CI 1.02-2.45, in patients with mild kidney dysfunction and normal 
function, respectively) and cardiovascular mortality (HR 0.75, 95% CI 0.62-0.90 versus HR 
1.15, 95 % CI 0.91-1.45, in patients with mild kidney dysfunction and normal function, 
respectively) [44]. Edoxaban 30 mg qd was associated even with greater risk of stroke and SE 
compared to warfarin.  
 
When further subdivided into groups according to CrCl cut off value of CrCl of 95 ml/min was 
found, for which edoxaban provided the efficacy similar to dose-adjusted warfarin (HR 1.02, 
95% CI 0.76-1.38). In patents with CrCl >95ml/min the risks of stroke and SE were in favor of 
warfarin therapy [44]. The poorer outcomes in patients with normal kidney function with 
edoxaban were suggested to be due to lower drug exposure given kidney clearance of edoxaban 
of 50%.  
 
However, interpretation of this finding has to be cautious, since it could be affected by range of 
facts, e.g., low number of events and patients with normal kidney function, demographic 
characteristics (lower stroke risk and younger age if patients with normal kidney function Ре
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compared to those with reduced one), good quality of anticoagulation with warfarin resulted in 
unexpectedly low rate of events in warfarin arm [45]. Assessment of rate of stroke and SE in 
patients on edoxaban also did not support low efficacy of edoxaban in patients with normal 
kidney function. It tended to increase from the lowest in patients with normal kidney function 
(1.26% per year) to mild and moderate kidney dysfunction (1.49% and 2.29% per year, 
respectively) [45]. 
 
Apparently, drug exposure affects clinical outcomes. In patients treated with dabigatran within 
the RE-LY (Randomized evaluation of long-term anticoagulation therapy) trial, over 5-fold 
variability of plasma concentration was observed that translated into concentration-dependent 
increase of bleeding complications, however risk of thromboembolic events appeared to be less 
dependent on concentration variability [46, 47].   
 
An analysis of the ENGAGE AF – TIMI 48 trial data was performed to assess whether 
adjustment of dose of edoxaban based on patients characteristics applied in the trial was 
sufficient alone to assure stable plasma concentrations, and eventually, anticoagulant (anti-FXa) 
activity as well as stroke/SE and bleeding events.  Reduction of edoxaban dose from 60 mg qd to 
30 mg qd decreased mean exposure by 29% (from 48.5 ng/ml to 34.6 ng/ml) and anti-FXa 
activity by 25% (from 0.85 IU/mL to 0.64 IU/ml). In the low dose edoxaban arm, concentration 
decreased by 35% (from 24.5 ng/ml to 16.0 ng/ml) and anti-FXa activity by 20% (from 0.44 
IU/ml to 0.35 IU/ml). Overall across all used dosing regimes three-fold and 2.4-fold variability 
of trough plasma concentration and anti-FXa activity was seen [48].  
 
Greater than expected reductions of concentration and anticoagulant effect however did not 
result in higher stroke/SE rate but ensured lower risk of bleeding [48]. Consistent with the 
dabigatran data [47], with increasing edoxaban concentration, a gradual, linear decrease in the Ре
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risk of stroke and SE events but steeper increase in the risk of major bleeding was observed [48]. 
Of note, a low probability of ICH with a relatively flat association was seen across edoxaban 
concentrations [48] in contrast to VKAs which are known to increase the risk of ICH in  
exponential manner with increasing anticoagulation intensity [49].  
 
In another pre-specified analysis impact of amiodarone administered concomitantly was studied 
[50]. Due to P-gp inhibition amiodarone results in increased edoxaban plasma concentration. The 
results of this study complemented the last one on drug concentration and efficacy and safety 
outcomes interplay. Amiodaron co-administration in patients taking low dose edoxaban led to 
significantly lower rate of the primary efficacy endpoint compared with warfarin versus patients 
not on amiodarone (HR 0.60, 95% CI 0.36–0.99, and HR 1.20, 95% CI 1.03–1.40, respectively; 
p for interaction <0.01), but it did not influence on major bleeding risk [50]. In patients taking 
high dose edoxaban amiodarone co-administration affected neither risk of stroke and SE nor rate 
of major bleeding [50]. Nonetheless these patients experienced more major and clinically 
relevant non-major bleedings compared with warfarin versus patients on high dose regime of 
edoxaban without amiodarone concomitantly (HR 1.12, 95% CI 0.91–1.36 versus HR 0.83, 95% 
CI 0.77–0.89, p for interaction 0.008) [50]. Suggested by Steffel et al explanation for this was 
based on clinical outcomes – drug concentration curves, e.g., increase in concentration of 
edoxaban against a low dose regime due to amiodarone occurred in steeper part of the curve for 
stroke or SE resulting in improvement of efficacy while shift of edoxaban concentration with a 
high dose regime of edoxaban with amiodarone concomitantly appeared to be within flat part of 
the curve. Vice versa, increase in concentration of edoxaban against a low dose regime due to 
amiodarone occurred in flat part of the curve for major bleeding but in steeper part with a high 
dose edoxaban regime [50]. 
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Finally, pre-specified echocardiographic analysis of left atrial structure and function was 
performed among the ENGAGE AF – TIMI 48 participants [51]. Left atrial remodeling is a 
cornerstone of AF pathogenesis [52]. Despite indices of left atrial structure and function have not 
been implicated yet into decision making process with respect to anticoagulation management on 
a routine basis they carry important information. Left atrial fibrosis was found to be associated 
with the CHADS2 score and stroke risk and even improved performance of stroke risk scores in 
several studies [52]. The analysis of echocardiographic data from the ENGAGE AF – TIMI 48 
trial also revealed relationship between left atrial dysfunction and the CHADS2 score. Moreover 
left atrial contractile dysfunction was observed in AF patients on sinus rhythm during 
examination that supported stroke prevention with OAC irrespectively of AF type [51].  
 
 
4. Regulatory affairs 
Ministry of Health, Labour and Welfare in Japan was the first regulatory authority that approved 
edoxaban for stroke and SE prevention in patients with non-valvular AF following 
announcement of results of ENGAGE AF – TIMI 48 trial (September 26, 2014) [53]. 
For the same indication edoxaban 60 mg qd in patients with CrCl >50 to ≤95 mL/min with dose 
reduction to 30 mg qd in patients with CrCl of 15 to 50 mL/min gained approval of US FDA 
(January 9, 2015). In the US edoxaban in patients with CrCl >95 ml/min should not be used [54].  
Next, Swissmedic, the regulatory authority of Switzerland, granted approval of edoxaban for 
stroke prevention in non-valvular AF (April 15, 2015) [55].  
In the Europe EMA approved edoxaban 60 mg qd for stroke prevention in non-valvular AF in 
patients with CrCl >50 mL/min (June 25, 2015) [56]. Dose reduction to 30 mg qd was 
recommended in case of moderate or severe renal impairment (CrCL of 15 to 50 mL/min), low 
body weight ≤60 kg, and concomitant use of the P-gp inhibitors (ciclosporin, dronedarone, 
erythromycin, or ketoconazole). General warning about a trend towards decreasing efficacy of Ре
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edoxaban with increasing CrCl observed for edoxaban compared to well-managed warfarin was 
included with no particular CrCL cut off level mentioned [56]. Shortly after edoxaban received 
EMA approval the National Institute for Health and Care Excellence (NICE) in the United 
Kingdom issued Final Appraisal Determination on Edoxaban for preventing stroke and SE in 
people with non-valvular atrial fibrillation with a similar to EMA dosing approach (August 26, 
2015) [57]. Importantly, several analyses confirmed the cost-effectiveness of edoxaban against 
warfarin for stroke prevention in AF [58, 59]. 
 
 
5. Laboratory monitoring  
Edoxaban has a stable and predictable anticoagulant effect without the need for laboratory 
monitoring of coagulation. Indeed, given the results of the pivotal phase III trials with NOACs 
versus warfarin, i.e. non-inferiority and often superiority of the NOAC both in terms of efficacy 
and safety outcomes, regular laboratory control in chronic anticoagulation is not needed.  
 
Laboratory measurement might be needed in cases of medications administered concomitantly 
and poor adherence to treatment or overdose. Laboratory testing may also aid decision-making 
on when to proceed with emergent invasive procedures or surgery, initiate thrombolytic therapy 
of ischaemic stroke to prevent haemorrhagic transformation, or stop haemostatic therapy to 
prevent prothrombotic effects [60, 61]. 
 
Despite effects of edoxaban on various coagulation parameters (e.g., PT, aPTT, INR), they are 
largely qualitative, and have nonlinear, exhibit wide variability and only modest correlation with 
edoxaban concentration [62]. For example, aPTT was elevated by average of 21% in 1.5 hour 
and 4% in 12 hours after edoxaban 60 mg taken orally [25] while doubling of aPTT level from 
baseline required drug concentration of 500 ng/ml that is more than two-fold higher compared to Ре
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maximum steady-state plasma concentration observed with edoxaban 60 mg qd regime in the 
phase II dose selection study [36, 63]. Better but still insufficient sensitivity was observed with 
PT assay [62].  
 
Apparently, only anti-FXa activity, also used for evaluation of anticoagulation with low 
molecular weight heparin (LMWH), offers reliable quantification of anticoagulation with 
edoxaban as it exhibits linearity across a broad range of drug concentrations[60, 62]. However, 
there is variability with high (above therapeutic level) edoxaban concentrations. Specific 
calibrated plasmas are expected to further improve diagnostic accuracy of anti-FXa assay 
because currently available data are based on use of LMWH standards for calibration [60, 62]. 
Anti-FXa assays are complex, expensive and not available in most clinics routinely 24 hours a 
day thus far.  
If anti-Xa assays are not available, a prolonged PT can be considered as evidence of circulating 
edoxaban. Nonetheless, PT or aPTT within normal range cannot rule out therapeutic 
concentration of edoxaban [62]. 
 
 
6. Adherence to anticoagulant therapy and real-world practice 
Non-requirement for regular laboratory monitoring is also believed to affect adherence to 
treatment. Good adherence to treatment is essential in AF patients under oral anticoagulation 
irrespectively of OAC chosen. However, the short half-life of edoxaban and once daily regime 
pose patient even at higher risk of stroke and SE in case of one missed dose compared to NOACs 
with twice a day dosing regime or warfarin that is known to maintain persistent anticoagulation 
effect within several days after last dose has been taken [15]. Nonetheless, regular monitoring is 
unlikely to improve adherence significantly because even with best available assays only last Ре
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taken dose can be evaluated while INR gives estimation of warfarin activity within several days 
before measurement. 
 
In the ENGAGE AF – TIMI 48 trial, there was a discontinuation rate of over 30% in both 
edoxaban arms and the warfarin arm, but rate of discontinuation due to non-adherence was not 
reported. Based on data obtained from real-world experience (that is currently lacking for 
edoxaban) adherence to anticoagulation seen in clinical trials does not necessarily translate to the 
everyday clinical practice that eventually affects treatment outcomes [40, 64]. For example in the 
prospective Dresden NOAC Registry primary end point of stroke or SE occurred with rate of 
2.88 and 0.86 %/year in patients treated with dabigatran 110 mg bid and 150 mg bid, 
respectively, versus 1.54 and 1.11 % year in the RE-LY trial. The discontinuation rate was found 
to be higher, at 25.8% versus 21.2% and 20.7% observed in the trial with low and high dose 
dabigatran, respectively [65, 66]. This was consistent with the data from cohort from Veteran 
Affairs hospitals with 27.8% patients classified as non-adherent (proportion of days covered 
below 80%) and non-adherence resulted in increased risk for combined end point of all-cause 
mortality and stroke (HR 1.13, 95% CI 1.07-1.19 per 10% decrease in proportion of days 
covered) [67].  
 
Noteworthy, real-world practice affects not only NOACs effectiveness and safety but also those 
of warfarin. For example, rates of stroke and major bleeding on warfarin were over three times 
higher among AF patients compared to those observed in the ARISTOTLE trial with apixaban: 
5.29 versus 1.51 per 100 person-years for stroke and 10.78 versus 3.09 per 100 person-years for 
major bleeding [68]. Recent analysis of large UK cohort of anticoagulant-naïve AF patients 
(n=27 514) the proportion remaining on OAC at one year was significantly higher with the 
NOACs (79.2%) than with VKAs (63.6%). This translated to persistence rate for patients with 
the CHA2DS2-VASc score of ≥ 2 (83.0 % versus 65.3%, respectively) [69]. Also patients on 
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rivaroxaban from the US database had a significantly better rate of persistence compared to those 
on warfarin (HR 0.63, 95% CI 0.59-0.68) and lower rate of discontinuation (HR 0.54, 95% CI 
0.49-0.58) [70].  
 
Nonetheless, plenty of studies also showed consistency of real-world data with those from 
pivotal trials on effectiveness, safety, and adherence to anticoagulation with NOACs. FDA 
analysis among Medicare beneficiaries with over 134 000 patients treated with dabigatran 
etexilate included and followed up for 37 500 person-years showed lower risk of ischaemic 
stroke (HR 0.80, 95% CI 0.67-0.96); ICH (HR 0.34, 95% CI 0.26-0.46) and mortality (HR 0.86, 
95%CI 0.77-0.96) when compared to AF patients taking warfarin. Higher rate of major 
gastrointestinal bleeding on dabigatran etexilate (HR 1.28, 95% CI 1.14-1.44), but no difference 
with respect to myocardial infarction (HR 0.92, 95% CI 0.78-1.08) were observed in this cohort 
[71]. When only anticoagulation-naïve patients were included broadly similar results were 
obtained. Dabigatran etexilate was associated with a lower risk of ischemic stroke or SE (HR 
0.86, 95% CI 0.79-0.93), hemorrhagic stroke (HR 0.51, 95% CI 0.40-0.65), and acute 
myocardial infarction (HR 0.88, 95% CI 0.77-0.99), and gastrointestinal bleeding (HR 1.11, 95% 
CI 1.02-1.22) [72]. Also Larsen et al found similar stroke or SE and major bleeding rates as well 
as lower mortality, ICH, pulmonary embolism, and MI with dabigatran etexilate compared with 
warfarin in the large Danish nationwide cohort [73].  
 
The prospective, observational study XANTUS (Xarelto for Prevention of Stroke in Patients 
With Atrial Fibrillation) also confirmed safety and effectiveness of another NOAC, rivaroxaban, 
in a real-world setting. The persistence with rivaroxaban was 80% at one year in this study. The 
stroke and major bleeding rates were even lower (0.7% versus 1.7% and 2.1% versus 3.6% 
events per 100 patient-years, respectively) in this unselected patient population than in ROCKET 
AF trial, however patients involved in the registry had lower stroke risk than in trial (CHADS2 
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2.0 versus 3.5, respectively) [74]. Laliberte et al did not found differences in real-world rates of 
composite stroke and SE and major, intracranial, or gastrointestinal bleeding with rivaroxaban 
and warfarin [75].  
 
Thus, despite missing so far real-world data on edoxaban, those available for other NOACs 
suggest them as a safe and effective alternative to warfarin in patients with AF managed in 
routine practice settings. Patient education is essential for patients taking OAC to improve their 
compliance, efficacy and safety of therapy irrespectively of anticoagulant being used [76, 77]. 
 
 
7. Bleeding and antidotes 
 
Despite lower rate of bleeding complications compared to warfarin therapy apart from 
gastrointestinal bleeding the risk of haemorrhage with edoxaban still exists. Both physicians and 
patients are concerned with the absence of specific antidote for the edoxaban and other NOACs. 
Thus far bleeding management includes general procedures like as local haemostasis, 
replacement of blood volume, discontinuation of next doses. Given relatively short half-life of 
edoxaban time is important curative factor with normalization of coagulation parameters 
achieved within one day in patients with normal renal function [78, 79].  
 
In the case of life-threatening bleeding rapid reversal of anticoagulation effect is required. 
Currently only non-specific reversal agents, that were approved for warfarin-associated bleeding, 
e.g., prothrombin complex concentrate (PCC), activated PCC, and recombinant factor VIIa are 
available for urgent reversal of anticoagulant effect of edoxaban [80, 81]. The use of these agents 
has not been supported by clinical trials but mostly preclinical in vitro and animal models. 
Moreover they are associated with procoagulant and prothrombotic effects and therefore should Ре
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only be considered in patients with life-threatening bleeding, when bleeding persists despite the 
ongoing use of standard haemostatic measures and haemodynamic support, or when longer than 
usual time for drug clearance is expected. Depending on severity of bleeding four-factor or three-
factor PCC in the dose of 25–50 IU/kg of body weight repeated once or twice can be chosen, 
while activated PCC and recombinant factor VIIa got less support [79, 81]. Local protocols 
addressing management of NOAC-related bleeding should be developed in hospital to facilitate 
patients care. 
 
Of note, the pivotal phase III trials, including ENGAGE AF-TIMI 48, were carried out in the 
absence of specific antidotes, but this did not translated into worse bleeding and mortality 
outcomes. PCC was used, and patients on warfarin required it even more frequently.  
 
There are two specific reversal agents for factor Xa inhibitors and one for direct thrombin 
inhibitor that are currently investigational [82]. Andexanet α, modified recombinant factor Xa 
have been developed as an antidote for factor Xa inhibitors. Andexanet α acts as a factor Xa 
decoy with high specificity to both oral and injectable factor Xa inhibitors in the circulation, 
hence, allowing intrinsic factor Xa to escape inhibition and take part in the coagulation cascade. 
Andexanet α is enzymatically inactive due to several modifications in comparison to normal 
factor Xa, for example, being unable to cause prothrombin activation and to bind to 
phospholipids in the prothrombinase complex. This agent works in a dose-dependent manner, 
and several phase III studies have been designed to study ability of andexanet α to reverse 
anticoagulation effect of apixaban and rivaroxaban (study with edoxaban is planning). For 
example, in the ANNEXA-A study with apixaban, its anticoagulant activity measured by anti-
FXa activity following the administration of a bolus of andexanet α was reduced by 93.5%. The 
latter effect was maintained by continuous infusion of reversal agent andexanet α with anti-FXa 
activity reduced by 92.7% two hours post-infusion. This was accompanied with significant Ре
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reduction of apixaban plasma concentration and restoration of thrombin generation in all subjects 
[83]. The ANNEXA-4 trial, a single-arm confirmatory study in patients receiving apixaban, 
rivaroxaban, edoxaban or enoxaparin who present with an acute major bleed is now ongoing 
[84]. 
 
In the model of major bleeding in rivaroxaban-treated animals andexanet α was shown to reduce 
blood loss significantly (>80%), as well as anti-FXa activity, PT and aPTT while therapeutic 
dose of four-factor PCC had no impact on any of these parameters [85].  
 
Another reversal agent ciraparantag (aripazine, PER977) is a small molecule which binds non-
covalently to anticoagulants, inhibiting the anticoagulant effects of factor Xa inhibitors, direct 
thrombin inhibitor dabigatran, LMWH, and fondaparinux. In the phase I study in patients who 
were administered edoxaban a single intravenous dose of ciraparantag (100 to 300 mg) 
resulted in recovery of the whole-blood clotting time to within 10% above the baseline value 
in ten minutes, and effect persisted up to 24 hours [86]. A Phase II clinical study with 
ciraparantag for edoxaban reversal is currently ongoing [87]. 
 
Idarucizumab is a specific reversal agent for dabigatran etexilate [46]. It is a fully humanized 
mouse monoclonal antibody fragment with at least 350 times higher affinity binding specific 
to dabigatran than to thrombin. Interim results of an ongoing phase III RE-VERSE AD study 
(A Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by 
Intravenous Administration of 5.0 g Idarucizumab [BI 655075] in Patients Treated With 
Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emergency Surgery or 
Procedures) [88] showed rapid and complete reversion of the anticoagulant activity of 
dabigatran in 88 to 98% of patients with no safety concerns among all the study participants 
[89] that was consistent with a preclinical data and studies in healthy volunteers [90-92]. 
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Thus, with availability of specific reversal agents for the NOACs anticoagulation 
management will become even safer and will contribute to confidence of their use. However, 
apparently definite protocols should be developed before reversal agents will be introduced 
into clinical practice, because laboratory (i.e., reversal or improvement of coagulation 
parameters) but not clinical (i.e., bleeding discontinuation) were used as primary study 
outcomes. Also due to differences in drugs pharmacology they will apparently require 
different regimes of reversal agents administration. 
 
8. Warfarin, edoxaban or other NOAC? 
 
With the idea that even one additional stroke risk factor poses patient with non-valvular AF at 
increased risk of stroke or SE development paradigm of stroke prevention shifted towards 
looking for low risk patients, i.e. those with AF and younger than 65 years. The rest simply 
needs effective stroke prevention with OAC [6].  
 
In the prospective observational PREFER in AF registry (Prevention of thromboembolic events 
– European Registry in Atrial Fibrillation) 85.6% of patients with CHA2DS2-VASc score ≥2 and 
70.1% of the patients with a CHA2DS2-VASc score of 1 received OAC reflecting 
implementation of the latest guidelines [93]. Notwithstanding the risk of OAC-associated 
bleeding patients are ready to tolerate 4.4 bleeding events to prevent one stroke [94]. However 
other questions arise: should we say now no to warfarin; to switch all patients to NOACs or not; 
and how to make an appropriate choice between range of available NOACs? 
 
Warfarin is known to be more versatile OAC that can be used in various clinical scenarios 
excluded from the pivotal stroke prevention clinical trials on NOACs based on study criteria or 
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negative results were obtained for NOACs. Such scenarios include end-stage kidney disease 
(CrCl below 30 or 15 ml/min depending on NOAC), acute coronary syndromes and stenting, 
valvular AF including mechanical prosthetic valves [15].  
 
For long-term OAC the major factor in favor of warfarin is a high TTR, the parameter closely 
associated with the quality of OAC management. The efficacy and safety of warfarin (or other 
VKAs) therapy are closely associated with high TTR, i.e. >70% (or >65%). Patients on warfarin 
in the NOACs trials had consistently good TTRs with the highest one observed in the ENGAGE 
AF-TIMI 48  trial but in the real-world setting TTRs tended to be lower [95].  Even patients with 
initially stable VKA treatment may develop extreme overanticoagulation episodically that is 
associated with a 2.3 times (95 % CI 2.0-2.5) higher risk for low TTR accompanied by increased 
risk of bleeding (HR 2.1, 95%CI 1.4-3.2), VKA-related death (HR 17.0, 95% CI 2.1-138), and 
thrombosis (HR 5.7, 95% CI 1.5-22.2) [96].  
 
Pharmacogenetic studies were attempted to improve patients selection and ensure high TTR. One 
analysis was performed in the ENGAGE AF – TIMI 48 cohort. Based on evaluation of 
polymorphisms of two genes, CYP2C9 and VKORC1, involved in warfarin metabolism, patients 
were classified into normal responders, sensitive and highly sensitive to warfarin patients. The 
two latter groups had a 31% and 2.66 times higher risk of bleeding within the first 90 days of 
treatment when compared with normal responders, respectively [97]. However genotyping 
showed only marginal improvement compared to standard of care. In a recent meta-analysis 
evaluated two approaches genotype-guided OAC improved TTR in comparison to fixed VKA 
dosing algorithms, but not with clinical algorithms, and it did not result in decreased composite 
of death, thromboembolism and major bleeding [98]. 
 Ре
по
зи
то
ри
й Г
рГ
М
У
 24
The SAMe-TT2R2 score was developed and validated in several cohorts to aid identifying 
patients with non-valvular AF who were expected to stay within therapeutic window and 
maintain a high average TTR with VKA (Table 5) [8, 99]. While the score was increasing from 0 
to ≥4 progressive decline of TTR from 67.5±24.6% to 52.7±28.7% was observed [100]. Despite 
moderate discrimination ability (c-statistic of 0.57) it allows in simple and practical way to 
distinguish the best candidates for OAC with warfarin, vs a NOAC. A SAMe-TT2R2 score of ≥2 
was associated with 1.64 (95 % CI 1.33–1.95) probability of low TTR. The ability of the 
stratification scheme to predict low TTR translated to its prognostic value for both stroke/SE and 
severe bleeding events [101]. The SAMe-TT2R2 score also allows avoiding of practice of ‘trial 
period with VKAs’ or ‘VKA stress test’, which often place patients at unnecessarily high risk of 
thromboembolic or bleeding complications [102]. 
 
One more important issue is a patient’s warfarin status. In the prespecified analysis of the 
ENGAGE AF – TIMI 48 trial high dose edoxaban appeared to be superior to warfarin for stroke 
and SE prevention in VKA-naïve patients (HR 0.71, 95% CI 0.56-0.90) but only non-inferior in 
VKA-experienced patients. Low dose edoxaban was similar to warfarin for stroke or SE 
prevention in patients who were VKA-naïve, but inferior VKA-experienced patients (HR 1.31, 
95% CI 1.08-1.60) [103]. Also, patients with history of stroke are prone to have lower TTR and 
higher bleeding risk, and thus, NOACs are likely to be beneficial in these patients [104]. 
 
The data from the NOACs trials were pooled in several systematic reviews and meta-analyses of 
which two included also data on edoxaban [105, 106]. NOACs were found to be superior to 
warfarin with respect to prevention of stroke and SE, haemorrhagic stroke, ICH, and all-cause 
mortality; non-inferior with respect to rate of ischaemic stroke and myocardial infarction. There 
was a trend towards reduced risk of major bleeding but more episodes of gastrointestinal 
bleeding were observed. Ре
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Thus, NOACs gained priority over VKAs in the European guidelines, but no preference was 
given to either of them in the American guidelines. European guidelines allow dual antiplatelet 
therapy of aspirin and clopidogrel for patients who deny OAC. Obviously such a therapy is 
inferior to OAC, including edoxaban, that was confirmed in indirect comparison analysis by 
Blann et al [77].  In the latter analysis, edoxaban 60 mg qd was associated with lower risk of 
stroke (relative risk [RR] 0.62, 95% CI 0.46-0.82), ischaemic stroke (RR 0.53, 95% CI 0.38-
0.73), and SE (RR 0.21, 95% CI 0.08-0.54) while trend in favor of edoxaban was observed for 
death (RR 0.88, 95% CI 0.74-1.05) and ICH (RR 0.64, 95% CI 0.35-1.2) [107].  
 
There were also several indirect comparison analyses performed evaluated NOACs, two of 
which included edoxaban [108, 109]. Despite all phase III trials used warfarin as an active 
comparator and all were performed in patients with non-valvular AF, the still had dissimilarities 
in methodology and patients characteristics that eventually might affect results of such an 
indirect comparison [40]. 
 
Dabigatran 150 mg bid was found to be superior to high dose edoxaban for prevention of such 
end points as stroke and SE (HR 0.75, 95% CI 0.56–0.99), stroke (HR 0.73, 95% CI 0.55–0.96), 
and haemorrhagic stroke (HR 0.48, 95% CI 0.23–0.99). There were more major bleedings with 
rivaroxaban (HR 1.30, 95% CI 1.08–1.57) but less major or clinically relevant non-major 
bleedings and gastrointestinal bleedings with apixaban (HR 0.79, 95% CI 0.70–0.90) compared 
to high dose edoxaban [109].  Low dose edoxaban appeared to be less effective for stroke and 
SE, any stroke and ischaemic stroke than all NOACs apart from dabigatran 110 mg bid. 
However low dose edoxaban was associated with significantly reduced rate of major bleeding 
(compared to all NOACs) and gastrointestinal bleeding (compared to all NOACs with exception Ре
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of apixaban) [109]. All the NOACs showed equal efficacy for reduction of cardiovascular and 
all-course mortality and safety with respect to ICH risk [109]. 
 
Taking into account extensive discussion of anticoagulant effect of the NOACs in patients with 
kidney impairment, all of them had similar efficacy and safety compared to warfarin across 
different levels of kidney function, but edoxaban and apixaban were associated with better safety 
profile. However, these results were also derived from indirect comparison analyses [110]. 
 
Have clinicians got the chance to tailor anticoagulation regimen to each individual patient? 
Apparently, such a selection based on indirect comparison analyses is largely speculative 
because of different trial cohorts. Indirect comparisons were performed to generate hypothesis 
which are unlikely to be tested in randomized clinical trials in near future. Huge data are 
necessary to collect to power the study with NOACs against each other, given their safety and 
efficacy obtained in the pivotal phase III trials.  
Thus far, high dose dabigatran, given its superiority over warfarin for ischaemic stroke and SE 
prevention (HR 0.65, 95% CI 0.52-0.81) and ischaemic (or uncertain) stroke prevention (HR 
0.76, 95% CI 0.60-0.98) might be considered in patients with the high CHA2DS2-VASc score, 
but in patients without dyspepsia since the latter is known to be the most common side effect and 
reason for non-adherence and discontinuation [46].  
 
In patients with a high bleeding risk (HAS-BLED score of ≥3) the NOACs associated with lower 
risk of major bleeding, i.e. low dose dabigatran (HR 0.80, 95% CI 0.70-0.93), apixaban (HR 
0.69, 95% CI 0.60-0.80), edoxaban (HR 0.80, 95% CI 0.71-0.91), are preferred [6, 15]. In 
patients with a history or risk of gastrointestinal bleeding apixaban might be recommended, since 
it did not result in increased gastrointestinal bleeding risk in the phase III trial. Patient’s Ре
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preferences to once daily dosing should be considered, and either rivaroxaban or edoxaban can 
be administered.  
 
 
9. Uncovered areas 
 
There are common clinical settings which may occur in patients with AF, but they were excluded 
from the ENGAGE AF – TIMI 48 trial because of study criteria, real-world experience because 
of recent approval is also lacking. This at least includes anticoagulation in patients with 
concomitant coronary heart disease and undergoing stenting, pericardioversion and periablation 
anticoagulation.  
 
Minimal duration of 3 weeks prior (unless absence of left atrial appendage thrombus is 
confirmed by transoesophageal echocardiography) and 4 weeks after cardioversion to prevent 
thromboembolic complications. In the X-VeRT trial (Rivaroxaban vs. vitamin K antagonists for 
cardioversion in atrial fibrillation) rivaroxaban showed the similar to warfarin rate of 
combination of stroke, TIA, SE, myocardial infarction and cardiovascular death. The rate of 
major bleeding was comparable too. The major advantage was significantly shorter time to 
cardioversion driven by long time spent for achievement of stable INRs in the warfarin arm 
[111]. Consistent results were obtained in the post-hoc analyses of phase III trials with 
rivaroxaban, apixaban, and dabigatran [15]. The largest cardioversion trial is ENSURE-AF 
(Edoxaban vs. warfarin in subjects undergoing cardioversion of atrial fibrillation), with 2200 
patients planned to be randomized edoxaban or warfarin and 2000 cardioversions performed 
[112].  This trial is ongoing now with results expected in 2016. 
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Catheter ablation of AF is also known to require OAC prior and after procedure. In the 
VENTURE-AF trial randomized patients undergoing catheter ablation of AF to uninterrupted 
consistently low rate of thromboembolic and bleeding events was observed [113]. Safety and 
efficacy profile was observed to be broadly similar for dabigatran versus warfarin [46], and also 
were addressed in the RE-CIRCUIT trial (Randomized evaluation of dabigatran etexilate 
compared to warfarin in pulmonary vein ablation: assessment of different peri-procedural 
anticoagulation strategies) [114].  
 
Finally, approximately 20% to 35% of AF patients also have coronary artery disease 
irrespectively of AF type, e.g., new onset, paroxysmal, persistent, and permanent. Up to half of 
these patients also develop myocardial infarction and/or undergo coronary stenting [115]. There 
was no increased risk of myocardial infarction in edoxaban arms of the ENGAGE AF – TIMI 48 
trial [39] as it was with dabigatran in the RE-LY trial [46], hence, edoxaban provides sufficient 
prevention of coronary events in stable patients. In patients with acute coronary syndrome and 
after stent implantation dual antiplatelet therapy (i.e. aspirin and clopidogrel) is needed to 
complement OAC (triple antithrombotic therapy), since either of them is not sufficient alone to 
prevent stroke and SE on the one hand, and stent thrombosis on the other.  
 
Current recommendations are based on experts consensus and do not advise to change NOAC to 
warfarin if this regime of OAC has been already well established. There is also no guidance for 
OAC selection in patients with new onset AF. Given that triple antithrombotic therapy is 
associated with significantly increased bleeding risk, lower available dose of NOAC should be 
used [116, 117]. 
 
In the small exploratory trial X-PLORER rivaroxaban caused suppression of coagulation 
activation as assessed with the levels of prothrombin fragments 1+2 and thrombin–antithrombin Ре
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complex in AF patients with CAD requiring elective percutaneous coronary intervention [118]. 
Two trials involving NOACs in AF patients treated with percutaneous coronary intervention are 
currently recruiting participants: the REDUAL-PCI trial comparing dual antithrombotic therapy 
regimen of dabigatran 110 mg bid or 150 mg bid plus clopidogrel or ticagrelor with a triple 
antithrombotic therapy of warfarin plus clopidogrel or ticagrelor plus low dose aspirin, and the 
PIONEER AF – PCI trial evaluating rivaroxaban 2.5 mg bid plus low-dose aspirin 75-100 mg qd 
and clopidogrel 75 mg qd (or prasugrel 10 mg qd, or ticagrelor 90 mg bid) followed by 
rivaroxaban 15 mg (or 10 mg for individuals with moderate renal impairment) qd plus low-dose 
aspirin for 12 months compared to the same regime but with dose-adjusted VKA instead of 
rivaroxaban [119, 120].   Other similar trials with apixaban and edoxaban have been announced. 
 
 
10. Conclusion 
 
In terms of efficacy and safety edoxaban is at least non-inferior to warfarin but also has 
important advantages which make edoxaban a favourable and convenient option for long-term 
anticoagulant treatment in non-valvular AF instead of less convenient warfarin.  While currently 
available evidence is represented by the large phase III ENGAGE AF – TIMI 48 trial mostly, 
many clinical scenarios that may occur in patients with AF requiring anticoagulation were 
omitted due to exclusion criteria.  
Following the approval of edoxaban data from ongoing and future trials as well as real-world 
registries will improve the knowledge on how to manage oral anticoagulation with edoxaban in 
routine clinical practice. 
 
 
11. Expert opinion 
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AF only rarely presents without other comorbidities or risk factors of thrombosis that essentially 
elevates risk of stroke and/or SE in this group of patients. Moreover strokes developing at a 
background of AF are known to be more severe and to have worse outcomes (e.g., higher 
probability of lethal outcome, more likely to develop recurrent stroke, more disabling, greater 
cognitive loss). Effective stroke prevention in AF means OAC, with benefit significantly 
exceeded risk of bleeding in patients with ≥1 stroke risk factors.  
 
Edoxaban is one of the non-vitamin K antagonist oral anticoagulants (NOACs), which were 
developed and introduced into clinical practice to improve management of AF patients by 
omitting major drawbacks of vitamin K antagonists, e.g. warfarin. Edoxaban as other NOACs 
has predictable anticoagulation effect with fixed dosing regime, fast onset and offset of action, 
non-requirement for laboratory monitoring, minor drug and food interactions.  
 
Low dose regime (30 mg qd) and high dose regime (60 mg qd) of edoxaban both appeared to be 
non-inferior to well-adjusted warfarin therapy in terms of stroke and SE prevention as assessed 
in the intention-to-treat analysis of the ENGAGE AF – TIMI 48 trial, but trend toward 
superiority was found for high dose edoxaban. Edoxaban also was found to be a safe drug with 
consistently lower rate of major bleeding, major and clinically relevant non-major bleeding and 
any bleeding. Only the risk of gastrointestinal bleeding was increased with high dose edoxaban 
that was obviously related to its pharmacokinetics. Both edoxaban dosages were associated with 
reduced risk cardiovascular mortality and intracranial haemorrhage. 
 
Nonetheless, the introduction of a new OAC drug in such a challenging area as oral 
anticoagulation raises new questions and not all of them have been answered thus far. There are 
common for all the NOACs issues of their use. Non-requirement of regular laboratory control is 
considered widely as one of factors amenable for lower adherence to treatment that given the Ре
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quick drug clearance may eventually lead to increased risk of stroke and SE. In the situation 
when degree of hypocoagulation can be measured reliably only with anti-factor Xa assay that is 
complex, expensive and not available in most institutions 24 hours a day, adherence is the key 
link between medical practice and patient outcome. Patients’ education therefore is of paramount 
importance to obtain as effective and safe anticoagulation as it was in the landmark trial. This 
might make anticoagulation with edoxaban even more beneficial since in patients who remained 
on treatment in the ENGAGE AF – TIMI 48 superiority over warfarin was observed. However 
real-world data do not always reflect precisely effects achieved in the highly selected cohort of 
clinical trial, and no results from everyday routine clinical practice are available thus far.  
 
One more issue shared with drugs in class is absence of clinically approved specific reversal 
agent that is may be necessary in case of life-threatening situations, e.g. haemorrhagic shock or 
when surgical intervention cannot be postponed. In less severe cases, time because of short half-
life time of edoxaban (and other NOACs) can be the major curative ‘agent’. Despite specific 
antidotes to edoxaban being desirable it is necessary to underline the fact that they were not 
available during testing in clinical trials but edoxaban was safer then well-managed warfarin. 
Knowledge of availability of specific antidote may improve the perception of edoxaban, both by 
patients and physicians and further improve adherence and outcomes.  
 
Kidney function is the important factor determining edoxaban exposure. Both moderate to severe 
reduction of eGFR (<50 ml/min), resulting in higher drug exposure and normal to mildly reduced 
eGFR (>80 ml/min), resulting in lower drug exposure, eventually affect effectiveness and safety 
of anticoagulation with edoxaban. Hence careful initial evaluation of kidney function and 
repetitive measurement during follow-up are essential to guide patient management. 
Appropriately adjusted doses were effective and safe in patients with suboptimal kidney function 
as confirmed in the ENGAGE AF-TIMI 48 trial. Ре
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Anticoagulation effect is also determined by such a pharmacokinetic characteristics that depends 
on frequency of drug intake, i.e. once or twice a day. Edoxaban showed even better safety and 
effectiveness with once a day dosing regime than the same daily dose divided into twice a day 
intake. Once a day dosing without tradeoff between safety and effectiveness may be additional 
favorable factor influencing on choice of edoxaban. 
 
The abovementioned limitations did not translate into worse clinical outcomes compared to 
warfarin. With the approval of edoxaban a new alternative both to vitamin K antagonists and 
other NOACs for stroke prevention in non-valvular AF has become available. Notwithstanding 
large experience obtained from phase 3 clinical trial with edoxaban versus warfarin for oral 
anticoagulation, some narrower areas are lacking firm evidence to date, e.g., pericardioversion 
and periablation use of edoxaban in patients with AF or in those with coronary heart disease 
undergoing stenting in either primary or elective setting. Ongoing and future trials and registries 
will resolve these current controversies in clinical practice. 
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Table 1. Stroke and bleeding risk stratification with the CHA2DS2-VASc [9] and HAS-
BLED [12] scores 
CHA2DS2-VASc Score HAS-BLED Score 
Congestive heart failure/LV 
dysfunction 
1 Hypertension (systolic blood 
pressure >160 mmHg) 
1 
Hypertension 1 Abnormal renal or liver 
function 
1 or 2 
Age ≥75 years 2 Stroke 1 
Diabetes mellitus 1 Bleeding tendency or 
predisposition 
1 
Stroke/TIA/TE 2 Labile INRs (if on warfarin) 1 
Vascular disease (prior MI, 
PAD, or aortic plaque) 
1 Age (e.g., >65, frail condition) 1 
Aged 65–74 years 1 Drugs (e.g., concomitant 
antiplatelet or NSAIDs) or 
alcohol excess/abuse 
1 or 2 
Sex category (i.e. female 
gender) 
1   
Maximum score 9  9 
 
CHA2DS2-VASc: heart failure [moderate-to-severe left ventricular systolic dysfunction refer to 
left ventricular ejection fraction ≤40% or recent decompensated heart failure requiring 
hospitalization], hypertension, age ≥75, diabetes, stroke/transient ischaemic attack [TIA], 
vascular disease [specifically, MI, complex aortic plaque and peripheral artery disease], age 65–
74 years, female sex. Ре
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HAS-BLED: uncontrolled hypertension, abnormal renal/liver function, stroke, bleeding history 
or predisposition, labile international normalized ratio [INR], elderly [e.g. age >65, frail 
condition], drugs [e.g., antiplatelet, non-steroidal anti-inflammatory drugs]/excessive alcohol. 
INR, international normalized ratio; LV, left ventricular; MI, myocardial infarction; NSAIDs, 
non-steroidal anti-inflammatory drugs; TIA/TE, transient ischemic attack/thromboembolism; 
PAD, peripheral artery disease. 
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Table 2. Pharmacological characteristics of edoxaban versus warfarin [54, 56, 121] 
Parameter Warfarin Edoxaban 
Mechanism of action Inhibition of VKORC1 Factor Xa inhibitor (free or 
bound), reversible 
Onset of action Slow, indirect inhibition of 
clotting factor synthesis 
Fast 
Offset of action Long Short 
Absorption Rapid Rapid 
Bioavailability, % >95 62 
Tmax, hour 2-4 1-2 
Vd, L 10 107 
Protein binding, % 99 55 
T1/2β, hour 40 10-14 
Renal clearance None 50 
Non-renal clearance None 50 
CL/F, L/hour 0.35 22 
Accumulation in plasma Dependent on CYP2C9 
metabolic efficiency 
None (accumulation ratio 
1.14) 
Food effect No effect on absorption; 
dietary vitamin K influence 
on pharmacodynamics 
None 
Age Yes, lower CL/F as age 
increases 
None (adjusted for body 
weight and kidney function) 
Body weight Yes, higher dose for 
increased weight 
Yes, increased total exposure 
in patients  with low body 
weight (median 55 kg) vs. 
high body weight (median 84 
kg) 
Sex Yes, lower CL/F in women None (adjusted for body 
weight) 
Ethnicity Lower dose in Asian patients; 
higher dose in African-
American patients 
Similar exposure in Asian 
and non-Asian patients 
Drug transporter None P-gp 
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CYP-mediated metabolism CYP2C9, CYP3A4, 
CYP2C19, CYP1A2 
Minimal (CYP3A4) 
Drug-drug interactions* Numerous Potent P-gp inhibitors (no 
dose reduction†) and inducers 
(avoid) 
Coagulation measurement INR Anti-FXa is preferred method 
Changes in PT, aPTT, INR 
are highly variable  
Reversal agents Vitamin K (slow reversal, 
prolonged inhibition), FFP or 
PCCs (rapid reversal) 
 
Andexanet, aripazine 
(investigational) 
PCCs, recombinant FVIIa 
Dosing for AF Individualised for each 
patient according to INR 
response (0.5-16 mg qd) 
60 mg qd in patients with 
CrCl of >50 to ≤ 95 mL/min. 
30 mg qd in patients with 
CrCl of 15 to 50 mL/min‡ 
 
AF, atrial fibrillation; aPTT, activated partial thromboplastin test; CL/F, apparent clearance; 
CrCl, creatinine clearance; CYP, cytochrom P450 isozymes; F, factor; FFP, fresh frozen plasma; 
INR, international normalized ratio; qd, once daily; PCC, prothrombin complex concentrate; P-
gp, Permeability glycoprotein; PT, prothrombin time; Tmax, time to maximum plasma 
concentration; T1/2β, terminal half-life, Vd, volume of distribution; VKORC1, vitamin K epoxide 
reductase enzyme subunit 1. 
 
* P-gp inhibitors include verapamil, amiodarone, quinidine, and certain macrolide antibiotics 
(e.g., erythromycin, azithromycin, and clarithromycin). P-gp inducers include rifampicin, St. 
John’s wort (Hypericum perforatum), carbamazepine, and phenytoin. Potent inhibitors of 
CYP3A4 include azole antifungals (e.g., ketoconazole, intraconazole, voriconazole, 
posaconazole), chloramphenicol, clarithromycin, and protease inhibitors (e.g., ritonavir, Ре
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atanazavir). Potent CYP3A4 inducers include phenytoin, carbamazepine, phenobarbital, and St. 
John’s wort. 
† US edoxaban labelling; reduced dose of 30 mg qd is recommended according to European 
edoxaban labelling 
‡ US edoxaban labelling; edoxaban 30 mg qd is recommended for patients with one or more of 
the following clinical factors: moderate or severe renal impairment (CrCL 15–50 mL/min), low 
body weight (≤ 60 kg), P-gp inhibitors (ciclosporin, dronedarone, erythromycin, ketoconazole) 
concomitantly according to European edoxaban labelling 
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Table 3. Summary of efficacy and safety of edoxaban in pivotal ENGAGE AF – TIMI 48 
trial in patients with non-valvular AF [39] 
Characteristics Warfarin Low dose edoxaban 
30 (15) mg qd 
High dose edoxaban 
60 (30) mg qd 
Patients  7036 7034 7035 
Age, years  72 72 72 
Mean CHADS2 score  2.8 2.8 2.8 
Prior vitamin K 
antagonist treatment, %  
58.8 59.2 58.8 
Prior stroke or transient 
ischemic attack, %  
28.3 28.5  28.1 
Mean TTR, warfarin 
arm; %  
68.4 NA NA 
Discontinuation rate, % 34.5 33.0 34.4 
End points, % of patients/year, HR (95% CI) 
Stroke or systemic 
embolism 
1.69 1.91 
1.13 (0.96-1.34) 
1.49 
0.87 (0.73-1.04)* 
Ischaemic stroke 1.25 1.77 
1.41 (1.19-1.67) 
1.25 
1.00 (0.83-1.19) 
Haemorrhagic stroke 0.47 0.16 
0.33 (0.22-0.50) 
0.26 
0.54 (0.38-0.77) 
Systemic embolism 0.12 0.15 
1.24 (0.72-2.15) 
0.08 
0.65 (0.34-1.24) 
All-cause mortality 4.35 3.80 
0.87 (0.79-0.96) 
3.99 
0.92 (0.83-1.01) 
Cardiovascular 
mortality 
3.17 2.71 
0.85 (0.76-0.96) 
2.74 
0.86 (0.77-0.97) 
Myocardial infarction  0.75 0.89 
1.19 (0.95-1.49) 
0.70 
0.94 (0.74-1.19) 
Major bleeding  3.43 1.61 
0.47 (0.41-0.55) 
2.75 
0.80 (0.71-0.91) 
Major or clinically 
relevant nonmajor 
bleeding 
13.02 7.97 
0.62 (0.57-0.67) 
11.10 
0.86 (0.80-0.92) Ре
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Intracranial hemorrhage  0.85 0.26 
0.30 (0.21-0.43) 
0.39 
0.47 (0.34-0.63) 
Gastrointestinal 
bleeding 
1.23 0.82 
0.67 (0.53-0.83)  
1.51 
1.23 (1.02-1.50) 
Any bleeding 16.4 10.68 
0.66 (0.62-0.71) 
14.15 
0.87 (0.82-0.92) 
 
* 97.5% confidence interval was used 
CI, confidence interval; HR, hazard ratio 
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Table 4. Consistency of results on the efficacy and safety of edoxaban across patient 
subgroups [54] 
Subgroups Outcomes Stroke and systemic embolism Major bleeding 
Warfarin 
%/year  
Edoxaban 
%/year 
HR (95% CI)* Warfarin 
%/year  
Edoxaban 
%/year 
HR (95% CI)* 
Age <65 1.11 1.05 0.94 (0.65-1.36) 1.81 1.45 0.80 (0.58-1.11) 
≥65 to <75 1.78 1.58 0.89 (0.68-1.16) 3.28 2.40 0.74 (0.58-0.93) 
≥75 2.31 1.91 0.83 (0.66-1.04) 4.67 3.90 0.84 (0.70-1.00) 
Gender Male 1.68 1.45 0.87 (0.71-1.07) 3.4 2.84 0.84 (0.72-0.99) 
Female 2.00 1.76 0.87 (0.69-1.11) 3.29 2.39 0.73 (0.58-0.91) 
Weight ≤60 2.91 2.53 0.88 (0.58-1.31) 4.44 2.95 0.67 (0.45-1.01) 
>60 1.69 1.47 0.87 (0.73-1.03) 3.26 2.65 0.82 (0.71-0.94) 
Stroke risk 
(CHADS2 
score) 
2 1.20 1.19 0.99 (0.76-1.29) 2.78 2.05 0.74 (0.60-0.91) 
≥3 2.39 1.91 0.80 (0.66-0.97) 3.94 3.28 0.84 (0.71-0.99) 
Kidney 
function  
(CrCl, 
mL/min) 
<30 2.61 2.41 - 5.07 3.83 0.76 (0.58-0.99) 
30-50 2.70 2.34 0.87 (0.64-1.19) 3.49 3.08 0.88 (0.73-1.07) 
>50-80 2.17 1.49 0.68 (0.54-0.86) 2.85 2.44 0.86 (0.60-1.22) 
>80 0.97 1.28 1.33 (0.97-1.81) 2.26 1.32 0.59 (0.41-0.84) 
Prior history of 
stroke/TIA 
Yes 2.85 2.44 0.86 (0.67-1.09) 3.56 3.06 0.87 (0.68-1.10) 
No 1.41 1.24 0.88 (0.72-1.08) 3.29 2.53 0.77 (0.66-0.90) 
Prior diabetes Yes 1.52 1.42 0.94 (0.71-1.25) 3.83 2.97 0.78 (0.63-0.96) 
No 1.96 1.65 0.84 (0.70-1.02) 3.10 2.52 0.81 (0.69-0.96) 
Warfarin at 
randomisation 
VKA-
experienced 
1.60 1.62 1.01 (0.82-1.24) 3.28  2.58 0.79 (0.67-0.93) 
VKA-naïve 2.12 1.49 0.71 (0.56-0.90) 3.49 2.83 0.82 (0.67-1.00) 
Aspirin at 
randomisation 
Yes 2.23 1.54 0.70 (0.53-0.92) 4.62 3.50 0.76 (0.62-0.94) 
No 1.63 1.58 0.97 (0.80-1.17) 2.86 2.35 0.82 (0.70-0.97) 
 
* HR <1.0 in favor of edoxaban, >1.0 in favor of warfarin 
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Table 5. Quality of anticoagulation control assessment with the SAMe-TT2R2 score [99] 
Sex category (i.e. female gender) 1 
Age <60 years 1 
Medical history (≥2 of the following: hypertension, DM, CAD/MI, PAD, 
CHF, previous stroke, pulmonary, hepatic or renal disease) 
1 
Treatment with interacting drugs(e.g., amiodarone) 1 
Tobacco use (within 2 years) 2 
Race (i.e. non-caucasian) 2 
 
CAD, coronary artery disease; CHF, congestive heart failure; DM, diabetes mellitus; MI, 
myocardial infarction; PAD, peripheral artery disease 
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